The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3
Abstract
The human MAGE‐3 gene is expressed in many tumors of several histological types but it is silent in normal tissues, with the exception of testis. Antigens encoded by MAGE‐3 may, therefore, be useful targets for specific anti‐tumor immunization of cancer patients. We reported previously that MAGE‐3 codes for an antigenic peptide recognized on a melanoma cell line by autologous cytolytic T lymphocytes (CTL) restricted by HLA‐A1. Here we report that the MAGE‐3 gene also codes for another antigenic peptide that is recognized by CTL restricted by HLA‐A2. MAGE‐3 peptides bearing consensus anchor residues for HLA‐A2 were synthesized and tested for binding. T lymphocytes from normal individuals were stimulated with autologous irradiated lymphoblasts pulsed with each of three peptides that showed strong binding to HLA‐A2. Peptide FLWGPRALV was able to induce CTL. We obtained CTL clones that recognized not only HLA‐A2 cells pulsed with this peptide but also HLA‐A2 tumor cell lines expressing the MAGE‐3 gene. The proportion of melanoma tumors expressing this antigen should be approximately 32 % in Caucasian populations, since 49 % of individuals carry the HLA‐A2 allele and 65 % of melanomas express MAGE‐3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Self-citationHansen, M. B., Nielsen, S. E., & Berg, K. (1989) · Journal of Immunological Methods · doi:10.1016/0022-1759(89)90397-9 · Cited by 3,507
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
Falk, K., Rötzschke, O., Stevanovié, S., Jung, G., & Rammensee, H.-G. (1991) · Nature · doi:10.1038/351290a0 · Cited by 2,411
Townsend, A. (1986) · Cell · doi:10.1016/0092-8674(86)90019-x · Cited by 1,699
Self-citationThe Role of the CD28 Receptor During T Cell Responses to Antigen
Linsley, P. S., & Ledbetter, J. A. (1993) · Annual Review of Immunology · doi:10.1146/annurev.iy.11.040193.001203 · Cited by 1,298
Espevik, T., & Nissen-Meyer, J. (1986) · Journal of Immunological Methods · doi:10.1016/0022-1759(86)90322-4 · Cited by 1,243
Tumor Antigens Recognized by T Lymphocytes
Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., & Van Pel, A. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002005 · Cited by 1,221
Self-citationCharacterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry
Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, H., Sevilir, N., Cox, A. L., Appella, E., & Engelhard, V. H. (1992) · Science · doi:10.1126/science.1546328 · Cited by 1,198
Binding of immunogenic peptides to Ia histocompatibility molecules
Babbitt, B. P., Allen, P. M., Matsueda, G., Haber, E., & Unanue, E. R. (1985) · Nature · doi:10.1038/317359a0 · Cited by 1,195
D'Andrea, A., Rengaraju, M., Valiante, N. M., Chehimi, J., Kubin, M., Aste, M., Chan, S. H., Kobayashi, M., Young, D., & Nickbarg, E. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.5.1387 · Cited by 1,144
Cited by
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
Self-citationHuman tumor antigens recognized by T lymphocytes.
Boon, T., & van der Bruggen, P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.725 · Cited by 842
Self-citationIkeda, H., Lethé, B., Lehmann, F., Van Baren, N., Baurain, J.-F., De Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80426-4 · Cited by 762
Self-citationA listing of human tumor antigens recognized by T cells
Renkvist, N., Castelli, C., Robbins, P. F., & Parmiani, G. (2001) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620000169 · Cited by 694
Van den Eynde, B. J., & van der Bruggen, P. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80050-7 · Cited by 623
Self-citationBAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes
Boël, P., Wildmann, C., Sensi, M. L., Brasseur, R., Renauld, J.-C., Coulie, P., Boon, T., & van der Bruggen, P. (1995) · Immunity · doi:10.1016/s1074-7613(95)80053-0 · Cited by 583
Self-citationVonderheide, R. H., Hahn, W. C., Schultze, J. L., & Nadler, L. M. (1999) · Immunity · doi:10.1016/s1074-7613(00)80066-7 · Cited by 570
Van den Eynde, B., Peeters, O., De Backer, O., Gaugler, B., Lucas, S., & Boon, T. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.3.689 · Cited by 567
Self-citationA New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens
Rosenberg, S. A. (1999) · Immunity · doi:10.1016/s1074-7613(00)80028-x · Cited by 566
Ferrone, S., & Marincola, F. M. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80033-6 · Cited by 474
A listing of human tumor antigens recognized by T cells: March 2004 update
Novellino, L., Castelli, C., & Parmiani, G. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0560-6 · Cited by 466
Jäger, E., Gnjatic, S., Nagata, Y., Stockert, E., Jäger, D., Karbach, J., Neumann, A., Rieckenberg, J., Chen, Y.-T., Ritter, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220413497 · Cited by 426
Coulie, P. G., Lehmann, F., Lethé, B., Herman, J., Lurquin, C., Andrawiss, M., & Boon, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7976 · Cited by 423
Self-citationTumor‐specific shared antigenic peptides recognized by human T cells
Van Der Bruggen, P., Zhang, Y., Chaux, P., Stroobant, V., Panichelli, C., Schultz, E. S., Chapiro, J., Van den Eynde, B. J., Brasseur, F., & Boon, T. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18806.x · Cited by 378
Self-citationHuman tumor antigens for cancer vaccine development
Wang, R., & Rosenberg, S. A. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01331.x · Cited by 296
Maeurer, M. J., Gollin, S. M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W. J., & Lotze, M. T. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118958 · Cited by 289
Expression of MAGE genes in primary and metastatic cutaneous melanoma
Brasseur, F., Rimoldi, D., Liénard, D., Lethé, B., Carrel, S., Arienti, F., Suter, L., Vanwijck, R., Bourlond, A., Humblet, Y., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630313 · Cited by 285
Self-citationKessler, J. H., Beekman, N. J., Bres-Vloemans, S. A., Verdijk, P., van Veelen, P. A., Kloosterman-Joosten, A. M., Vissers, D. C. J., ten Bosch, G. J. A., Kester, M. G. D., Sijts, A., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.1.73 · Cited by 263
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
Metadata
- Authors
- van der Bruggen, P., Bastin, J., Gajewski, T., Coulie, P. G., Boël, P., De Smet, C., Traversari, C., Townsend, A., & Boon, T.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 1994-12
- Volume
- 24
- Issue
- 12
- Pages
- 3038-3043
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2149940155
- Cited by
- 367
- References
- 42
- FWCI
- 13.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.